Signaling Substances Used in Plant Defense: HPLC-MS/MS Analysis of Jasmonates
by Tim Iven, Kirstin Feussner, Cornelia Herrfurth, and Elmar Herbig
Volume 14, Issue 4 (Winter 2015/2016)
Plants must be capable of responding to climatic fluctuations, diurnal rhythms, available supplies of water and nutrients, and insect attacks and infestations. To ensure such responses, plants need a network of regulating substances called phytohormones. These substances enable plants to respond to both biotic and abiotic stresses by initiating a cascade of orchestrated actions, and to trigger development-specific processes. In this article, we will discuss a highly sensitive analytical method for quantitative determination of phytohormones. The main representatives of the plant hormones are jasmonic acid (JA), cytokines, auxins, abscisic acid, salicylic acid, gibberellins, and strigolactones...
Citation:
Iven T, Feussner K, Herrfurth C, Herbig E. Signaling substances used in plant defense: HPLC-MS/MS analysis of jasmonates. BioProcess J, 2016; 14(4): 56–61. http://dx.doi.org/10.12665/J144.Herbig.
Posted online January 12, 2016.
Improving Biopharmaceutical Manufacturing Yield Using Neural Network Classification
by Will Fahey and Paula Carroll
Volume 14, Issue 4 (Winter 2015/2016)
Traditionally, the Six Sigma framework has underpinned quality improvement and assurance in biopharmaceutical manufacturing process management. This paper proposes a neural network (NN) approach to vaccine yield classification and compares it to an existing multiple linear regression approach. As part of the Six Sigma process, this paper shows how a data mining framework can be used to extract further value and insight from the data gathered during the manufacturing process, and how insights into yield classification can be used in the quality improvement process...
Citation:
Fahey W, Carroll P. Improving biopharmaceutical manufacturing yield using neural network classification. BioProcess J, 2016; 14(4): 39–50. http://dx.doi.org/10.12665/J144.Carroll.
Posted online January 12, 2016.
|
Influence of Cell Disruption Methods on the Recovery and Immunogenicity of a Fusion Protein for a Therapeutic Cancer Vaccine Against HPV
by Miladys Limonta, Laura Varas, Jorge Valdés, Lourdes Zumalacárregui, Dayana Soler, Maelys Miyares, Alain B. Alfonso, Milaid Granadillo, and Isis Torrens
Volume 14, Issue 4 (Winter 2015/2016)
Two cell disruption methods, mechanical and chemical, were applied for the recovery of a fusion protein named CIGB 550-E7, expressed on Escherichia coli grown in defined saline media. A comparison of the methods was done, and various operating parameters for each technique were optimized to obtain the maximum disruption efficiency and CIGB 550-E7 protein release. The mechanical disruption’s yield and recovery were 1.24 and 1.37 times higher than those obtained with chemical disruption. Modified conditions were assayed for the CIGB 550-E7 obtained by chemically defined media using the mechanical and chemical cell disruption methods. The processes we developed allowed us to obtain an active pharmaceutical ingredient that fulfills the requirements stipulated by the regulatory authorities in terms of purity and lipopolysaccharide contaminants. In addition, the CIGB 550-E7 obtained from both methods showed similar biological activity so that either method could be used. Finally, a cost/benefit relationship (CBR) analysis was done for both disruption methods, and the CBR value for mechanical cell disruption demonstrated that this was the most feasible choice...
Citation:
Limonta M, Varas L, Valdés J, Zumalacárregui L, Soler D, Miyares M, Alfonso AB, Granadillo M, Torrens I. Influence of cell disruption methods on the recovery and immunogenicity of a fusion protein for a therapeutic cancer vaccine against HPV. BioProcess J, 2016; 14(4): 22–9. http://dx.doi.org/10.12665/J144.Limonta.
Posted online January 12, 2016.
Biopharmaceutical Manufacturing: Current Titers and Yields in Commercial-Scale Microbial Bioprocessing
by Ronald A. Rader and Eric S. Langer
Volume 14, Issue 4 (Winter 2015/2016)
This article reports the average titers and yields currently attained with commercially manufactured biopharmaceuticals expressed by microbial systems such as E. coli and yeasts. A recent BioProcessing Journal article comparably covered results from the first phase of this study concerning historical titers and yields attained for commercial-scale biopharmaceutical production using mammalian cells (e.g., CHO). As with this prior mammalian component, public domain data concerning titers and yields attained with microbially manufactured products were obtained using all available sources. These included a review of available literature and direct contact with over 200 bioprocessing professionals identified as involved in relevant product research and development, and manufacturing. Unexpectedly, current microbial titers with commercially manufactured products were found to be consistent with those previously determined for mammalian products. However, purification yields attained with microbial manufacturing averaged only about 15%. This is much lower than with mammalian products yielding approximately 69%. Despite low downstream yields, microbial bioproduction continues to be considered less costly, simpler, faster, and generally more economical than mammalian manufacturing...
Citation:
Rader RA, Langer ES. Biopharmaceutical manufacturing: current titers and yields in commercial-scale microbial bioprocessing. BioProcess J, 2016; 14(4): 51–5. http://dx.doi.org/10.12665/J144.Langer.
Posted online January 12, 2016.
|
